Display options
Cite
Nace GW, Steel JL, Amesur N, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011;2011:571261doi: 10.1155/2011/571261.
Nace, G. W., Steel, J. L., Amesur, N., Zajko, A., Nastasi, B. E., Joyce, J., Sheetz, M., & Gamblin, T. C. (2011). Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. International journal of surgical oncology, 2011571261. https://doi.org/10.1155/2011/571261
Nace, Gary W, et al. "Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience." International journal of surgical oncology vol. 2011 (2011): 571261. doi: https://doi.org/10.1155/2011/571261
Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, Sheetz M, Gamblin TC. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011;2011:571261. doi: 10.1155/2011/571261. Epub 2011 Mar 20. PMID: 22312513; PMCID: PMC3263679.
Copy Download .nbib Format: NLM
Share it on

Int J Surg Oncol. 2011;2011:571261. doi: 10.1155/2011/571261. Epub 2011 Mar 20.

Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience.

International journal of surgical oncology

Gary W Nace, Jennifer L Steel, Nikhil Amesur, Albert Zajko, Bryon E Nastasi, Judith Joyce, Michael Sheetz, T Clark Gamblin

Affiliations

  1. Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

PMID: 22312513 PMCID: PMC3263679 DOI: 10.1155/2011/571261

Abstract

Purpose. We sought to evaluate our experience using yttrium-90 ((90)Y) resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC). Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with (90)Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent (90)Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first (90)Y treatment was 10.2 months (95% CI = 7.5-13.0). The absence of extrahepatic disease at the time of treatment with (90)Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4-27.6), compared to those with extrahepatic disease at the time of treatment with (90)Y, 6.7 months (95% CI = 2.7-10.6 CONCLUSION: (90)Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status.

References

  1. Ann Oncol. 2001 Dec;12(12):1711-20 - PubMed
  2. N Engl J Med. 2004 Jun 3;350(23):2335-42 - PubMed
  3. J Vasc Interv Radiol. 2006 Aug;17(8):1251-78 - PubMed
  4. Radiology. 2008 May;247(2):507-15 - PubMed
  5. J Vasc Interv Radiol. 2008 Aug;19(8):1187-95 - PubMed
  6. Ann Surg. 1989 Aug;210(2):127-38 - PubMed
  7. J Surg Oncol. 2004 Nov 1;88(2):78-85 - PubMed
  8. J Gastrointest Surg. 2001 May-Jun;5(3):294-302 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 - PubMed
  10. BMC Cancer. 2005 Oct 15;5:132 - PubMed
  11. Aust N Z J Surg. 1992 Feb;62(2):105-10 - PubMed
  12. Am J Pathol. 1954 Sep-Oct;30(5):969-77 - PubMed
  13. J Clin Oncol. 2007 Apr 20;25(12):1539-44 - PubMed
  14. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):13-23 - PubMed
  16. J Surg Oncol. 1989 Nov;42(3):192-6 - PubMed
  17. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 - PubMed
  18. Intern Med J. 2005 Apr;35(4):222-7 - PubMed
  19. Semin Surg Oncol. 1996 Jul-Aug;12(4):219-52 - PubMed
  20. J Vasc Interv Radiol. 2005 Jul;16(7):937-45 - PubMed
  21. Cancer. 2009 May 1;115(9):1849-58 - PubMed
  22. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 - PubMed
  23. In Vivo. 2006 Nov-Dec;20(6A):711-4 - PubMed
  24. ANZ J Surg. 2006 Aug;76(8):696-703 - PubMed

Publication Types

Grant support